41 results
DEFA14A
HARP
Harpoon Therapeutics Inc
8 Jan 24
Additional proxy soliciting materials
5:20pm
will be introducing our 2024 priorities shortly.
b. Interactions with Merck will be limited to their leadership and integration teams as directed by the Harpoon … senior leadership team (SLT) There should be no communication at the program and project levels until the closing of the acquisition.
5. Will Merck
DFAN14A
HARP
Harpoon Therapeutics Inc
8 Jan 24
Additional proxy materials by non-management
5:15pm
cancer immunotherapy candidates to improve the lives of patients. With Merck’s recognized leadership in oncology clinical development and global
DEFA14A
HARP
Harpoon Therapeutics Inc
8 Jan 24
Additional proxy soliciting materials
8:04am
immunotherapy candidates to improve the lives of patients. With Merck’s recognized leadership in oncology clinical development and global commercial footprint
8-K
EX-99.2
HARP
Harpoon Therapeutics Inc
8 Jan 24
Entry into a Material Definitive Agreement
8:01am
, we have always been committed to advancing our cancer immunotherapy candidates to improve the lives of patients. With Merck’s recognized leadership
8-K
EX-99.1
hwewbiyrj5 9tv
11 May 23
Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
9:07pm
PRE 14A
9ym 3uj24n
14 Apr 23
Preliminary proxy
4:54pm
8-K
EX-99.1
q230bunr
10 Aug 22
Harpoon Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:14pm
8-K
EX-99.1
lbgwjgn
10 Nov 21
Harpoon Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
4:41pm